Skip to main content

Table 4 Comparison of PBMC cellular content relative to elutriated fraction 5 from patients with early stage prostate cancer and multiple myeloma and other advanced stage cancers

From: Counter-flow elutriation of clinical peripheral blood mononuclear cell concentrates for the production of dendritic and T cell therapies

 

n

WBCs (×109)

RBCs (×109)

Platelets (×109)

Neutrophils (×109)

Lymphs (×109)

Monos (×109)

Loaded

      

Prostate Cancer

28

14.1 ± 4.5

212.6 ± 130.2

524.9 ± 196.5

1.56 ± 1.69

9.66 ± 3.39

2.58 ± 1.49

Multiple Myeloma*

31

16.6 ± 3.6#

188.4 ± 83.7

421.3 ± 178.7#

2.03 ± 2.04

10.3 ± 3.15

3.64 ± 2.04#

Fraction 5

      

Prostate Cancer

28

3.59 ± 2.18

1.02 ± 1.88

0.24 ± 0.29

1.29 ± 1.99

0.086 ± 0.09

2.11 ± 0.81

Multiple Myeloma*

31

4.66 ± 1.81$

0.28 ± 0.76

0.09 ± 0.20$

1.32 ± 1.54

0.22 ± 0.20$

2.98 ± 1.22$

  1. The values shown are mean ± 1 standard deviation.
  2. *Includes patients with multiple myeloma and cancers other than prostate cancer.
  3. #p < 0.05 for comparison of the quantity of cells loaded in the elutriator among patients with prostate cancer and multiple myeloma and other advanced cancers.
  4. $p < 0.05 for comparison of the quantity of cells in fraction 5 among patients with prostate cancer and multiple myeloma and other advanced cancers.